Skip to main content
Keira Smith

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

Rahul Banerjee and Shonali Midha discuss updates on bispecific antibodies in multiple myeloma from the IMS 2023 Meeting.

At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  

Continue reading
Tags:
multiple myeloma Rahul Banerjee Shonali Midha IMS teclistamab
Keira Smith

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

Rahul Banerjee and Shonali Midha discuss updates on bispecific antibodies in multiple myeloma from the IMS 2023 Meeting.

At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  

Continue reading
Tags:
podcast Rahul Banerjee Shonali Midha multiple myeloma teclistamab
Keira Smith

Teclistamab Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli®, Janssen Biotech) for adult patients with relapsed/refractory multiple myeloma previously treated with four or more lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistimab is the first bispecific B-cell maturation antigen (BCMA)–directed CD3 T-cell engager. "Standard treatment of multiple myeloma includes the administration of immunomodulatory agents, p...

Continue reading
Tags:
multiple myeloma FDA approval teclistamab BCMA Philippe Moreau